DTIL
Income statement / Annual
Last year (2024), Precision BioSciences, Inc.'s total revenue was $68.70 M,
an increase of 40.98% from the previous year.
In 2024, Precision BioSciences, Inc.'s net income was $7.17 M.
See Precision BioSciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$68.70 M |
$48.73 M |
$25.10 M |
$115.53 M |
$24.29 M |
$22.24 M |
$10.88 M |
$6.48 M |
$7.02 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$68.70 M
|
$48.73 M
|
$25.10 M
|
$115.53 M
|
$24.29 M
|
$22.24 M
|
$10.88 M
|
$6.48 M
|
$7.02 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$59.56 M
|
$53.38 M
|
$46.12 M
|
$115.24 M
|
$98.06 M
|
$82.42 M
|
$45.12 M
|
$20.32 M
|
$9.10 M
|
| General & Administrative Expenses |
$35.30 M
|
$39.09 M
|
$41.28 M
|
$39.67 M
|
$36.05 M
|
$27.03 M
|
$13.67 M
|
$8.02 M
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$35.30 M
|
$39.09 M
|
$41.28 M
|
$39.67 M
|
$36.05 M
|
$27.03 M
|
$13.67 M
|
$8.02 M
|
$6.10 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$94.86 M
|
$92.46 M
|
$87.41 M
|
$154.91 M
|
$134.11 M
|
$109.44 M
|
$58.80 M
|
$28.34 M
|
$15.20 M
|
| Cost And Expenses |
$94.86 M
|
$92.46 M
|
$87.41 M
|
$154.91 M
|
$134.11 M
|
$109.44 M
|
$58.80 M
|
$28.34 M
|
$15.84 M
|
| Interest Income |
$6.76 M
|
$7.69 M
|
$3.47 M
|
$208.00 K
|
$822.00 K
|
$4.27 M
|
$1.88 M
|
$872.00 K
|
$570.00 K
|
| Interest Expense |
$1.78 M
|
$2.23 M
|
$1.11 M
|
$132.00 K
|
$0.00
|
$182.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$4.58 M
|
$8.26 M
|
$9.00 M
|
$10.20 M
|
$9.81 M
|
$5.32 M
|
$2.35 M
|
$1.44 M
|
$640.00 K
|
| EBITDA |
$13.53 M |
-$32.04 M |
-$62.79 M |
-$20.27 M |
-$99.19 M |
-$87.38 M |
-$43.68 M |
-$20.42 M |
-$8.19 M |
| EBITDA Ratio |
0.2
|
-0.66
|
-2.5
|
-0.18
|
-4.08
|
-3.93
|
-4.01
|
-3.15
|
-1.17
|
| Operating Income Ratio |
-0.38
|
-0.9
|
-2.48
|
-0.34
|
-4.52
|
-3.92
|
-4.4
|
-3.39
|
-1.26
|
| Total Other Income/Expenses Net |
$33.33 M
|
$1.21 M
|
-$10.60 M
|
$8.77 M
|
$822.00 K
|
-$5.67 M
|
$1.88 M
|
$872.00 K
|
$572.00 K
|
| Income Before Tax |
$7.17 M
|
-$42.53 M
|
-$72.91 M
|
-$30.60 M
|
-$109.01 M
|
-$92.88 M
|
-$46.04 M
|
-$21.10 M
|
-$8.26 M
|
| Income Before Tax Ratio |
0.1
|
-0.87
|
-2.9
|
-0.26
|
-4.49
|
-4.18
|
-4.23
|
-3.25
|
-1.18
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$5.00 K
|
| Net Income |
$7.17 M
|
-$61.32 M
|
-$111.64 M
|
-$30.60 M
|
-$109.01 M
|
-$92.88 M
|
-$46.04 M
|
-$21.10 M
|
-$8.25 M
|
| Net Income Ratio |
0.1
|
-1.26
|
-4.45
|
-0.26
|
-4.49
|
-4.18
|
-4.23
|
-3.25
|
-1.18
|
| EPS |
1.05 |
-15.96 |
-38.1 |
-15.6 |
-62.85 |
-59.5 |
-28.17 |
-18.81 |
-0.49 |
| EPS Diluted |
1.04 |
-15.96 |
-38.1 |
-15.6 |
-62.85 |
-59.5 |
-28.17 |
-18.81 |
-0.49 |
| Weighted Average Shares Out |
$6.83 M
|
$3.84 M
|
$2.93 M
|
$1.96 M
|
$1.73 M
|
$1.40 M
|
$1.63 M
|
$1.12 M
|
$16.74 M
|
| Weighted Average Shares Out Diluted |
$6.88 M
|
$3.84 M
|
$2.93 M
|
$1.96 M
|
$1.73 M
|
$1.40 M
|
$1.63 M
|
$1.12 M
|
$16.74 M
|
| Link |
|
|
|
|
|
|
|
|
|
